|
18.05.2015 22:25:00
|
Par Pharmaceutical Companies, Inc. -- Moody's reviews Par Pharma's ratings for upgrade
New York, May 18, 2015 -- Moody's Investors Service placed the ratings of Par Pharmaceutical Companies, Inc. ("Par") under review for upgrade, including the B2 Corporate Family Rating and the B2-PD Probability of Default Rating. At the same time, Moody's affirmed Par's SGL-1 Speculative Grade Liquidity Rating.
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.